Harry Langbeheim Ph.D. CEO
Dr. Langbeheim has more than 20 years of experience in the diagnostics and life science industry as CEO of Life Science Research Israel Ltd., VP & COO at Savyon Diagnostics Ltd. and as Director of R&D at Sigma Immunochemicals. Over the last ten years, Dr. Langbeheim has served as independent marketing and business consultant to early-stage Israeli companies. He graduated as Dipl.Nat.Sc. from the ETH in Zurich, Switzerland and received a Ph.D. in Immunology from the Weizmann Institute of Science, Rehovot.
Zvi Dannenberg, Chairman of the Board
Mr. Dannenberg is an entrepreneur and active businessman. He was born in Israel and grew up in Belgium, where he founded and managed a medium-sized computer firm. After selling the company, he moved to Israel with his family. Today Mr. Dannenberg, a registered pilot, owns a small aviation company. He provided the financing for the acquisition of the CPA technology and for its further development and currently serves as the CEO of Matis Medical (Israel) Ltd. which is responsible of the research and development of the CPA.
David Varon MD, Medical Director
Prof. Varon is the co-founder of Matis and has more than 25 years of experience in the field of hematology and internal medicine. He earned his B.Sc Biology and MD from the Sackler School of Medicine at Tel Aviv University in 1972 and 1976, respectively. Prof. Varon is the director of the Thrombosis and Hemostasis Unit, Department of Hematology at Hadassah Medical School, Hebrew University, Jerusalem. Prior to this position, Prof. Varon served as the deputy director of the Israeli national hemophilia center, spent three years as a fellow and visiting scientist at NYU medical Center and at the Scripps Clinic at La Jolla Ca.
During the last 20 years Prof. Varon led research in the field of platelet physiology and R&D studies both at Sheba Medical Center and at Hadassah, which were awarded over $1.7 million. His studies yielded 4 patents, one of which is already licensed. Prof. Varon has founded the Israel Society of Thrombosis and Hemostasis, is a member of the Israel Society of Hematology, International Society of Thrombosis and Hemostasis and the American Society of Hematology. In addition, he is a member of the editorial board of the Journals Pathophysiology of Thrombosis and Haemostasis, and Harefua, and an active reviewer for the journals: Blood, Journal of Thrombosis and Haemostasis (JTH), Thrombosis and Haemostasis (T&H), Thrombosis Research, IMAJ, Harefua. He has published over 100 papers in leading professional journals.
Naphtali Savion, Ph.D., Chief Technology Officer
Prof. Savion is the co-founder of Matis and is a cell biology expert, specialized in the fields of growth factors (in particular FGF), vascular biology, platelets, bone cells in culture, and cells - extracellular matrix interaction. He is a Professor of Clinical Biochemistry at Sackler Faculty of Medicine at Tel Aviv University and is the Head of Cell Biology Laboratory at the Goldschleger Eye Research Institute, Sheba Medical Center, Tel Hashomer. Prof. Savion holds a Doctorate in Biochemistry from the Hebrew University of Jerusalem and held a postdoctoral fellowship at the Cancer Research Institute of the University of California.
For the past 24 years Prof. Savion has led a research group at Tel Aviv University which was awarded $850,000 for its research activities, and has led other R&D projects with a total budget of over $1.6 million. He has published over 130 papers in leading professional journals and has participated in more than 80 international meetings. He registered 4 patents of which 2 were licensed and reached the Market. Prof. Savion served as a Scientific Consultant to ColBar LifeScience and currently he serves as a Scientific Board Member at TeraVitae.
Garret E. Bergman, MD, Member of the Board
Garrett E. Bergman, M.D., holds a Masters in Business Administration from Temple University School of Business and Management, a Doctorate in Medicine from Jefferson Medical College, and a Bachelor of Science degree from Pennsylvania State University. Dr. Bergmann serves as Senior Director Medical Affairs, U.S. Commercial Operations of ZLB Behring. After a distinguished academic career, Dr. Bergman served at Rorer, Armour Pharmaceutical and RPR, which later became ZLB Behring. He also served at Centeon LLC from 1989 to 1997, in the Medical Affairs Department. Most recently, Dr. Bergman served as the Vice President, Research and Development for Octagen Corporation.
Noam Danenberg, Member of the Board
Mr. Danenberg received his MBA from Boston University with a specialization in global tax planning. Mr. Danenberg is the co-founder of various companies in the field of computers, high-tech and medical devices. He is the CEO of Fitracks, a private company developing, manufacturing and marketing a medical computer, which customizes inner soles for shoes.